Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.69 USD | +0.73% | +6.95% | -30.93% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 541M |
---|---|---|---|---|---|
Net income 2024 * | -134M | Net income 2025 * | -166M | EV / Sales 2024 * | - |
Net cash position 2024 * | 82.2M | Net cash position 2025 * | 129M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.02
x | P/E ratio 2025 * |
-3.71
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.08% |
Latest transcript on Olema Pharmaceuticals, Inc.
1 day | +0.73% | ||
1 week | +6.95% | ||
Current month | +0.10% | ||
1 month | -4.72% | ||
3 months | -21.85% | ||
6 months | -30.54% | ||
Current year | -30.93% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Kushner
FOU | Founder | 86 | 06-08-06 |
Sean Bohen
CEO | Chief Executive Officer | 57 | 20-08-31 |
Cyrus Harmon
FOU | Founder | 53 | 06-08-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Clark
CHM | Chairman | 62 | 20-07-31 |
J. Garland
BRD | Director/Board Member | 55 | 23-10-15 |
Andy Rappaport
BRD | Director/Board Member | 66 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.59% | 4 M€ | -5.15% | - | |
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 9.68 | +0.62% | 992,776 |
24-05-30 | 9.62 | -0.31% | 1,327,094 |
24-05-29 | 9.65 | +4.32% | 1,091,260 |
24-05-28 | 9.25 | +2.10% | 634,818 |
24-05-24 | 9.06 | +3.78% | 625,146 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.93% | 542M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- OLMA Stock